Mesutoclax

N/A

Report date: 2026/04/14 20:00:15
NME

Base Information

Drug NameMesutoclax
Drug Alias NameICP-248
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionApoptosis regulator Bcl-2 inhibitors
TargetsApoptosis regulator Bcl-2
Therapy Area/IndicationsMyelodysplastic SyndromesHematologic NeoplasmsLymphoma, Mantle-Cell +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesUkrainePuerto Rico +[5] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesInnoCare Pharma Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesInnoCare Pharma IncInnoCare Pharma LtdBeijing Innocare Pharma Tech Co Ltd
Inactive CompaniesN/A
Active IndicationsMyelodysplastic SyndromesHematologic NeoplasmsLymphoma, Mantle-Cell +[7] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A